SCHEMBL2414647

SCHEMBL2414647

CC(=O)N1CC[C@H](CS(=O)(=O)c2nnnn2-c2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.48
MAPT P10636 7/20 0.48
LMNA P02545 5/20 0.45
HTT P42858 4/20 0.45
TP53 P04637 3/20 0.45
HPGD P15428 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HSD17B10 Q99714 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
TSHR P16473 1/20 0.43
HSD11B1 P28845 1/20 0.39
TACR3 P29371 1/20 0.39
GFER P55789 1/20 0.39
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2416198 0.93 ALDH1A1 (0.50) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL2413883 0.91 ALDH1A1 (0.52) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL632936 0.86 GPR119 (0.47) ALDH1A1MAPTLMNATP53
SCHEMBL19433476 0.81 ALDH1A1 (0.62) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL18686925 0.79 ALDH1A1 (0.59) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL13083703 0.78 ALDH1A1 (0.58) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL11895011 0.76 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL11895013 0.76 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL2415550 0.74 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL16559929 0.73 ALDH1A1 (0.50) ALDH1A1MAPTLMNAHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 EP disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
WO-2011068211-A1 2-PYRIDONE COMPOUNDS 大正製薬株式会社 (JP) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237791-A1 2-PYRIDONE COMPOUNDS PDXK, HK1, KCNJ2 ALDH1A1 2239/4885MAPT 532/4885LMNA 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.